Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saatci, Ozge, Kaymak, Aysegul, Raza, Umar, Ersan, Pelin G., Akbulut, Ozge, Banister, Carolyn E., Sikirzhytski, Vitali, Tokat, Unal Metin, Aykut, Gamze, Ansari, Suhail A., Dogan, Hayriye Tatli, Dogan, Mehmet, Jandaghi, Pouria, Isik, Aynur, Gundogdu, Fatma, Kosemehmetoglu, Kemal, Dizdar, Omer, Aksoy, Sercan, Akyol, Aytekin, Uner, Aysegul, Buckhaults, Phillip J., Riazalhosseini, Yasser, Sahin, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229173/
https://www.ncbi.nlm.nih.gov/pubmed/32415208
http://dx.doi.org/10.1038/s41467-020-16199-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229173/
https://www.ncbi.nlm.nih.gov/pubmed/32415208
http://dx.doi.org/10.1038/s41467-020-16199-4

Ejemplares similares